KR102537018B1 - 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도 - Google Patents

카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도 Download PDF

Info

Publication number
KR102537018B1
KR102537018B1 KR1020177013734A KR20177013734A KR102537018B1 KR 102537018 B1 KR102537018 B1 KR 102537018B1 KR 1020177013734 A KR1020177013734 A KR 1020177013734A KR 20177013734 A KR20177013734 A KR 20177013734A KR 102537018 B1 KR102537018 B1 KR 102537018B1
Authority
KR
South Korea
Prior art keywords
compound
formula
pharmaceutically acceptable
dopa
carbidopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177013734A
Other languages
English (en)
Korean (ko)
Other versions
KR20170071599A (ko
Inventor
베노이트 카디날-데이비드
빈센트 에스. 챈
카시블라 이. 뎀파
브라이언 피. 엔라이트
로저 에프. 헨리
라이문도 호
예 황
알렉산더 디. 후터스
러셀 시. 클릭스
스콧 더블유. 크라브
필립 알. 킴
옌빈 라오
샤오춘 러우
신 이. 맥키
마크 에이. 마툴렌코
피터 티. 메이어
크리스토퍼 피. 밀러
제임스 스탐불리
에릭 에이. 보이트
즈 왕
제프 지. 장
발렌티노 제이. 스텔라
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102537018(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Priority to KR1020237015051A priority Critical patent/KR20230066484A/ko
Publication of KR20170071599A publication Critical patent/KR20170071599A/ko
Application granted granted Critical
Publication of KR102537018B1 publication Critical patent/KR102537018B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177013734A 2014-10-21 2015-10-21 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도 Active KR102537018B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237015051A KR20230066484A (ko) 2014-10-21 2015-10-21 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
US62/066,771 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015051A Division KR20230066484A (ko) 2014-10-21 2015-10-21 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도

Publications (2)

Publication Number Publication Date
KR20170071599A KR20170071599A (ko) 2017-06-23
KR102537018B1 true KR102537018B1 (ko) 2023-05-30

Family

ID=54478240

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020177013734A Active KR102537018B1 (ko) 2014-10-21 2015-10-21 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도
KR1020237015051A Ceased KR20230066484A (ko) 2014-10-21 2015-10-21 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도
KR1020247023761A Pending KR20240113982A (ko) 2014-10-21 2015-10-21 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237015051A Ceased KR20230066484A (ko) 2014-10-21 2015-10-21 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도
KR1020247023761A Pending KR20240113982A (ko) 2014-10-21 2015-10-21 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도

Country Status (37)

Country Link
US (7) US9446059B2 (cg-RX-API-DMAC10.html)
EP (3) EP3209302B1 (cg-RX-API-DMAC10.html)
JP (6) JP6567049B2 (cg-RX-API-DMAC10.html)
KR (3) KR102537018B1 (cg-RX-API-DMAC10.html)
CN (4) CN107206013A (cg-RX-API-DMAC10.html)
AR (1) AR102389A1 (cg-RX-API-DMAC10.html)
AU (4) AU2015335941B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017008198B1 (cg-RX-API-DMAC10.html)
CA (1) CA2965379A1 (cg-RX-API-DMAC10.html)
CY (2) CY1121826T1 (cg-RX-API-DMAC10.html)
DK (1) DK3209302T3 (cg-RX-API-DMAC10.html)
ES (1) ES2739536T3 (cg-RX-API-DMAC10.html)
FI (1) FIC20230014I1 (cg-RX-API-DMAC10.html)
FR (1) FR23C1035I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20191285T1 (cg-RX-API-DMAC10.html)
HU (2) HUE044115T2 (cg-RX-API-DMAC10.html)
IL (3) IL251829B (cg-RX-API-DMAC10.html)
LT (2) LT3209302T (cg-RX-API-DMAC10.html)
LU (1) LUC00304I2 (cg-RX-API-DMAC10.html)
MX (2) MX381069B (cg-RX-API-DMAC10.html)
MY (1) MY189519A (cg-RX-API-DMAC10.html)
NL (1) NL301224I2 (cg-RX-API-DMAC10.html)
NO (1) NO2023013I1 (cg-RX-API-DMAC10.html)
PH (1) PH12017500746B1 (cg-RX-API-DMAC10.html)
PL (1) PL3209302T3 (cg-RX-API-DMAC10.html)
PT (1) PT3209302T (cg-RX-API-DMAC10.html)
RS (1) RS58972B1 (cg-RX-API-DMAC10.html)
RU (2) RU2743347C2 (cg-RX-API-DMAC10.html)
SA (1) SA521421115B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201703170RA (cg-RX-API-DMAC10.html)
SI (1) SI3209302T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201900376T1 (cg-RX-API-DMAC10.html)
TR (1) TR201908296T4 (cg-RX-API-DMAC10.html)
TW (2) TWI755257B (cg-RX-API-DMAC10.html)
UA (1) UA120437C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016065019A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201702760B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
ES2739536T3 (es) * 2014-10-21 2020-01-31 Abbvie Inc Profármacos de carbidopa y L-dopa y su uso para tratar la enfermedad de Parkinson
US20190224220A1 (en) * 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
US11148999B2 (en) 2016-06-22 2021-10-19 MedChem Partners, LLC Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
PT3713933T (pt) 2017-11-24 2026-05-19 H Lundbeck As Novos profrmacos de catecolamina para utilizao no tratamento de doena de parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
CN112770734B (zh) 2018-09-13 2024-08-20 堪培拉大学 抑制方法
TW202031265A (zh) * 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US12391650B2 (en) 2019-05-21 2025-08-19 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
EP3972600B1 (en) 2019-05-21 2026-02-18 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
WO2020234275A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
MX2023010450A (es) * 2021-03-10 2023-09-14 Neuroderm Ltd Composiciones liquidas estabilizadas que comprenden un conjugado de tirosina y levodopa, y usos de estas.
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
EP0393781B1 (en) * 1989-04-20 1995-02-08 ZAMBON GROUP S.p.A. Dopamine pro-drug
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
AU1457299A (en) * 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
AU2003244088A1 (en) 2002-06-20 2004-01-06 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
MXPA06002344A (es) 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
RU2006118801A (ru) 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
AU2005252220B2 (en) * 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
EP1773850B1 (en) 2004-07-06 2013-01-30 Abbott Laboratories Prodrugs of hiv protease inhibitors
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
KR20090057349A (ko) * 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파/칼비도파의 24시간의 장기간 장내투여
WO2007144422A2 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
KR101444979B1 (ko) * 2008-02-06 2014-10-07 욱크하르트 리미티드 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス, インコーポレイテッド 水溶性アセトアミノフェン類似体
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
PT3192500T (pt) 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
CA2789236C (en) 2009-11-09 2014-09-09 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
DK2640358T3 (en) 2010-11-15 2018-04-16 Neuroderm Ltd CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS THEREOF
ES2529129T3 (es) 2010-12-02 2015-02-17 Ono Pharmaceutical Co., Ltd. Nuevo compuesto y uso médico del mismo
EP2648716A4 (en) 2010-12-10 2015-05-20 Synagile Corp PRODUCT COMPOSITIONS OF SUVUTABLY PERFUSABLE LÉVODOPA
WO2012158527A2 (en) * 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
HUE056006T2 (hu) 2013-03-13 2022-01-28 Neuroderm Ltd Kombináció Parkinson-kór kezelésére
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
ES2739536T3 (es) 2014-10-21 2020-01-31 Abbvie Inc Profármacos de carbidopa y L-dopa y su uso para tratar la enfermedad de Parkinson
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
US20190224220A1 (en) 2016-04-20 2019-07-25 Abbvie Inc. Carbidopa and L-Dopa Prodrugs and Methods of Use
US20190224153A1 (en) 2016-09-29 2019-07-25 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
JP2017537066A (ja) 2017-12-14
BR112017008198B1 (pt) 2021-02-09
AU2021201414B2 (en) 2023-05-11
US11091507B2 (en) 2021-08-17
SI3209302T1 (sl) 2019-06-28
LT3209302T (lt) 2019-06-10
SA521421115B1 (ar) 2022-03-01
CA2965379A1 (en) 2016-04-28
HRP20191285T1 (hr) 2019-10-18
NL301224I1 (cg-RX-API-DMAC10.html) 2023-03-29
WO2016065019A1 (en) 2016-04-28
PL3209302T3 (pl) 2019-10-31
CN107206013A (zh) 2017-09-26
LTC3209302I2 (cg-RX-API-DMAC10.html) 2025-10-10
RS58972B1 (sr) 2019-08-30
EP3209302B1 (en) 2019-04-24
HUS2300009I1 (hu) 2023-03-28
EP3569587A1 (en) 2019-11-20
IL268885B (en) 2020-08-31
NO2023013I1 (no) 2023-03-20
KR20240113982A (ko) 2024-07-23
IL251829A0 (en) 2017-06-29
US10174061B2 (en) 2019-01-08
PH12017500746A1 (en) 2017-10-30
LUC00304I2 (cg-RX-API-DMAC10.html) 2025-09-22
IL276493A (en) 2020-09-30
NZ769153A (en) 2024-04-26
EP4186510A1 (en) 2023-05-31
TWI755257B (zh) 2022-02-11
JP2025118978A (ja) 2025-08-13
US10730895B2 (en) 2020-08-04
RU2021103000A (ru) 2021-03-01
PT3209302T (pt) 2019-07-19
FR23C1035I2 (fr) 2025-04-18
JP7688087B2 (ja) 2025-06-03
JP2020189864A (ja) 2020-11-26
JP2021183628A (ja) 2021-12-02
CN111362980B (zh) 2022-10-18
KR20170071599A (ko) 2017-06-23
US20190375770A1 (en) 2019-12-12
JP2019218356A (ja) 2019-12-26
MX393568B (es) 2025-03-24
SG11201703170RA (en) 2017-05-30
PH12017500746B1 (en) 2021-12-15
TW201630924A (zh) 2016-09-01
TWI718999B (zh) 2021-02-21
AU2015335941B2 (en) 2021-04-01
MX2017005236A (es) 2017-07-26
AU2023210650A1 (en) 2023-08-24
TR201908296T4 (tr) 2019-06-21
RU2743347C2 (ru) 2021-02-17
TW202131931A (zh) 2021-09-01
US20180079762A1 (en) 2018-03-22
US20160106765A1 (en) 2016-04-21
US20160362431A1 (en) 2016-12-15
AU2015335941A1 (en) 2017-05-04
CY2023010I2 (el) 2023-06-09
JP6750076B2 (ja) 2020-09-02
KR20230066484A (ko) 2023-05-15
DK3209302T3 (da) 2019-05-13
ES2739536T3 (es) 2020-01-31
MX2021003840A (es) 2022-06-30
FIC20230014I1 (fi) 2023-03-31
NL301224I2 (nl) 2023-08-16
IL251829B (en) 2019-09-26
JP6567049B2 (ja) 2019-08-28
US20200262852A1 (en) 2020-08-20
CN111362980A (zh) 2020-07-03
JP6932227B2 (ja) 2021-09-08
AU2025238004A1 (en) 2025-10-16
LTPA2023519I1 (cg-RX-API-DMAC10.html) 2023-06-26
NZ730996A (en) 2024-04-26
RU2017117413A (ru) 2018-11-26
CN111454290A (zh) 2020-07-28
US20220153765A1 (en) 2022-05-19
AU2021201414A1 (en) 2021-03-25
CY2023010I1 (el) 2023-06-09
HUE044115T2 (hu) 2019-10-28
MX381069B (es) 2025-03-12
CN111494395B (zh) 2024-06-21
SMT201900376T1 (it) 2019-09-09
US9446059B2 (en) 2016-09-20
MY189519A (en) 2022-02-16
UA120437C2 (uk) 2019-12-10
AR102389A1 (es) 2017-02-22
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
JP2023174770A (ja) 2023-12-08
CY1121826T1 (el) 2020-07-31
CN111494395A (zh) 2020-08-07
RU2017117413A3 (cg-RX-API-DMAC10.html) 2019-05-30
EP3209302A1 (en) 2017-08-30
ZA201702760B (en) 2022-05-25
US20230106081A1 (en) 2023-04-06
CN111454290B (zh) 2022-12-23
IL268885A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7688087B2 (ja) カルビドパおよびl-ドーパプロドラッグならびにそれらの使用方法
US20240024338A1 (en) Carbidopa and l-dopa prodrugs and methods of use
HK40092679A (en) Intermediates and process for preparing l-dopa diphosphate
HK40017405A (en) Intermediates and process for preparing l-dopa diphosphate
HK40034110A (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK1240507B (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
HK1240507A1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200911

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220926

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230224

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230523

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230524

End annual number: 3

Start annual number: 1

PG1601 Publication of registration